(PRWEB) November 27, 2009
Based upon proprietary Nexus6 technology and designed with feedback from clinicians and respiratory researchers, SmartTrack® records and reports patient medication adherence to prescribed inhaled corticosteroid and combination therapies.
SmartTrack® is intended for single-patient use as an electronic data capture system
Current applications for the SmartTrack® system include the management of Asthma and Chronic Obstructive Pulmonary Disease (COPD). It is estimated that up to 34 million Americans have been diagnosed with asthma during their lifetime, and more than 10 million US adults suffer from COPD. Nexus6 Limited can supply adherence monitors for all major existing inhalation drug delivery devices marketed by global pharmaceutical companies.
Asthma and COPD are only two diseases where poor medication adherence is recognized as a cause of significant waste in worldwide healthcare systems. The New England Healthcare Institute (NEHI) estimates that in the United States alone nonadherence, along with suboptimal prescribing, drug administration, and diagnosis results in as much as US$290 billion per year in avoidable medical spending, and up to US$100 billion each year in excess hospitalization costs.
David Evans, Chief Executive Officer of Nexus6 said “The FDA approval is a very important company milestone, but it is only a starting point for Nexus6, since the SmartTrack® knowledge platform system has broad application in intelligent systems to improve the management of other diseases. We already have commercial contracts in place with global manufacturers of medical devices for treatment of disease states other than asthma and COPD to incorporate our technology into their next generation products”.
Nexus6 Limited is a privately held developer and manufacturer of solutions to increase patient adherence to therapies, leading to improved disease management and reduced healthcare costs.
Garth Sutherland, COO
(937) 274 2111 ext 104